Replies to post #223664 on Amarin Corp Plc (AMRN)

[rosemountbomber]

Yep Sharinky, could also cause a rise in price if briefing docs are viewed as benign.

[Biobillionair]

Shar- You are spot on, briefing documents that contain surprises can severely drop PPS of single drug companies moving into Ad Com. JT was wise to detail topics of discussions...yes he got exhausted at the end of the call and could have wrapped up Yee’s 2 questions in 30 seconds but oh well...

There’s nothing left to FUD...trial design and integrity can be subdivided into countries, secondary and primary events separated at different times, and blood epa levels don’t lie....

I don’t expect the stock to move much until GS truly value peak sales based on labeling.

IMO Vascepa will be assigned a very wide primary label...FDA doesn’t want First Amendment introduced again. Additionally the FDA would appear as obstructing standard of care if the label isn’t medically accurate....read the pre-Ad Com posts....very heavy support from very experienced clinicians.

BB